Summit Therapeutics Inc
SMMT26.660USD
-0.080-0.30%
Close 07/30, 16:00（ET）Quotes delayed by 15 min
19.77BMarket Cap
LossP/E TTM
More Details of Summit Therapeutics Inc Company
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Company Info
Ticker SymbolSMMT
Company nameSummit Therapeutics Inc
IPO dateOct 14, 2004
Founded at2020
CEODr. Mahkam (Maky) Zanganeh
Number of employees159
Security typeOrdinary Share
Fiscal year-endOct 14
Address601 Brickell Key Drive
CityMIAMI
Stock exchangeNASDAQ Global Market Consolidated
CountryUnited States of America
Postal code33131
Phone13052032034
Websitehttps://www.smmttx.com/
Ticker SymbolSMMT
IPO dateOct 14, 2004
Founded at2020
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Robert William (Bob) Duggan
Mr. Robert William (Bob) Duggan
Executive Chairman of the Board, Co-Chief Executive Officer
Executive Chairman of the Board, Co-Chief Executive Officer
555.75M
+0.01%
Dr. Mahkam (Maky) Zanganeh
Dr. Mahkam (Maky) Zanganeh
President, Co-Chief Executive Officer, Director
President, Co-Chief Executive Officer, Director
35.74M
+1.02%
Dr. Yu (Michelle) Xia
Dr. Yu (Michelle) Xia
Non-Executive Director
Non-Executive Director
31.52M
--
Mr. Manmeet S. Soni, CPA
Mr. Manmeet S. Soni, CPA
Chief Financial Officer, Chief Operating Officer, Director
Chief Financial Officer, Chief Operating Officer, Director
--
--
Mr. Robert Lacaze
Mr. Robert Lacaze
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Kenneth A. Clark, J.D.
Mr. Kenneth A. Clark, J.D.
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Robert F. Booth, Ph.D.
Dr. Robert F. Booth, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Mostafa Ronaghi, Ph.D.
Dr. Mostafa Ronaghi, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Jeffrey (Jeff) Huber
Mr. Jeffrey (Jeff) Huber
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Robert William (Bob) Duggan
Mr. Robert William (Bob) Duggan
Executive Chairman of the Board, Co-Chief Executive Officer
Executive Chairman of the Board, Co-Chief Executive Officer
555.75M
+0.01%
Dr. Mahkam (Maky) Zanganeh
Dr. Mahkam (Maky) Zanganeh
President, Co-Chief Executive Officer, Director
President, Co-Chief Executive Officer, Director
35.74M
+1.02%
Dr. Yu (Michelle) Xia
Dr. Yu (Michelle) Xia
Non-Executive Director
Non-Executive Director
31.52M
--
Mr. Manmeet S. Soni, CPA
Mr. Manmeet S. Soni, CPA
Chief Financial Officer, Chief Operating Officer, Director
Chief Financial Officer, Chief Operating Officer, Director
--
--
Mr. Robert Lacaze
Mr. Robert Lacaze
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Kenneth A. Clark, J.D.
Mr. Kenneth A. Clark, J.D.
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
Latin America
0.00
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Jul 29
Updated: Tue, Jul 29
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Duggan (Robert William)
74.83%
Zanganeh (Mahkam)
4.81%
Xia (Yu)
4.24%
Baker Bros. Advisors LP
3.29%
The Vanguard Group, Inc.
1.57%
Other
11.25%
Shareholders
Shareholders
Proportion
Duggan (Robert William)
74.83%
Zanganeh (Mahkam)
4.81%
Xia (Yu)
4.24%
Baker Bros. Advisors LP
3.29%
The Vanguard Group, Inc.
1.57%
Other
11.25%
Shareholder Types
Shareholders
Proportion
Individual Investor
84.32%
Investment Advisor
6.66%
Hedge Fund
4.18%
Investment Advisor/Hedge Fund
2.38%
Research Firm
0.39%
Bank and Trust
0.07%
Pension Fund
0.02%
Sovereign Wealth Fund
0.01%
Other
1.96%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
428
726.72M
97.85%
-882.09K
2025Q1
437
723.14M
98.66%
+648.97K
2024Q4
388
717.73M
97.33%
+5.42M
2024Q3
325
708.90M
96.17%
+11.45M
2024Q2
260
692.13M
98.13%
+14.08M
2024Q1
228
669.32M
95.38%
+36.91M
2023Q4
210
620.08M
88.82%
-5.65M
2023Q3
205
616.45M
88.38%
+11.96M
2023Q2
199
619.05M
88.77%
+407.10M
2023Q1
178
604.96M
86.79%
+406.66M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Duggan (Robert William)
555.75M
74.83%
+74.55K
+0.01%
May 30, 2025
Zanganeh (Mahkam)
35.74M
4.81%
+359.73K
+1.02%
Apr 15, 2025
Xia (Yu)
31.52M
4.24%
--
--
Apr 15, 2025
Baker Bros. Advisors LP
24.42M
3.29%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
11.64M
1.57%
-30.07K
-0.26%
Mar 31, 2025
Fidelity Management & Research Company LLC
9.31M
1.25%
+1.29M
+16.12%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
7.51M
1.01%
-43.09K
-0.57%
Mar 31, 2025
T. Rowe Price Associates, Inc.
6.46M
0.87%
-11.97K
-0.19%
Mar 31, 2025
State Street Global Advisors (US)
4.85M
0.65%
-751.52K
-13.41%
Mar 31, 2025
Geode Capital Management, L.L.C.
3.28M
0.44%
+84.03K
+2.63%
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
Tema Oncology ETF
2.79%
ProShares Ultra Nasdaq Biotechnology
1.8%
Invesco Nasdaq Biotechnology ETF
1.51%
SPDR S&P Biotech ETF
1.11%
Virtus LifeSci Biotech Clinical Trials ETF
0.99%
Invesco NASDAQ Next Gen 100 ETF
0.89%
Invesco ESG NASDAQ Next Gen 100 ETF
0.64%
Direxion Daily S&P Biotech Bull 3X Shares
0.61%
Goldman Sachs Equal Weight US Large Cap Equity ETF
0.23%
iShares Biotechnology ETF
0.22%
View more
Tema Oncology ETF
Proportion2.79%
ProShares Ultra Nasdaq Biotechnology
Proportion1.8%
Invesco Nasdaq Biotechnology ETF
Proportion1.51%
SPDR S&P Biotech ETF
Proportion1.11%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.99%
Invesco NASDAQ Next Gen 100 ETF
Proportion0.89%
Invesco ESG NASDAQ Next Gen 100 ETF
Proportion0.64%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.61%
Goldman Sachs Equal Weight US Large Cap Equity ETF
Proportion0.23%
iShares Biotechnology ETF
Proportion0.22%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
